Log In
BCIQ
Print this Print this
 

BION-007

  Manage Alerts
Collapse Summary General Information
Company Aduro Biotech Inc.
DescriptionAnti-CTLA-4 (CD152) mAb
Molecular Target Cytotoxic T-lymphocyte associated protein 4 (CTLA4) (CD152)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$63.5M

$16.2M

$28.7M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/30/2015

$63.5M

$16.2M

$28.7M

Get a free BioCentury trial today